Navigation Links
A simple blood test for colon cancer
Date:11/20/2008

People are often reluctant to undergo a routine but painful colonoscopy ― but the consequences can be fatal. According to the American Cancer Society, colon cancer is the third most common cancer found in American men and women and kills about 50,000 Americans every year.

"85% of those who develop colon cancer have no symptoms or family history," says Prof. Nadir Arber, a professor of medicine and gastroenterology, at Tel Aviv University's Sackler Faculty of Medicine. "Generally speaking, it's much harder to get these people to comply with taking the test."

To convince more people to undergo the potentially life-saving colonoscopy, Prof. Arber has developed a simple early-warning test that can detect colon cancer in the blood. Using biomarkers, it is the first test on the market that can detect cells of colon polyps the precursors to colon cancer in the blood, with a very high degree of sensitivity and accuracy.

This painless, non-invasive and inexpensive test could very well be a breakthrough of the decade.

An Attractive Diagnostic Step

"If we can identify those who are prone to cancer through a less invasive test, we can convince them to do the colonoscopy," leading to earlier detection and treatment, says Prof. Arber, who heads the Integrated Cancer Prevention Center at the Tel Aviv Souraski Medical Center.

Now being prepared for the market by Bio Mark Ltd., a subsidiary of Micromedic Technologies Ltd., Prof. Arber's "CD24" test could begin to save thousands of Americans' lives by as early as 2010. With the test, doctors can catch polyp growth in the colon in 80% of patients.

The American Cancer Society suggests that all Americans over the age of 50 receive periodic colonoscopies. With Prof. Arber's test, doctors will be able to screen patients for colon cancer quickly and easily as part of a routine blood test. While not 100% accurate, it will provide a convincing argument for patients to undergo the colonoscopy, and then polyp removal, if necessary.

The novel invention is based on testing CD24, the oncogene for colorectal cancer. It utilizes the fact that polyps in the colon emit biomarkers, which can be detected in the blood at very low levels. Recent studies show that the test can correctly identify adenomas, the polyps that convert to colon cancer, at a success rate of more than 80%.

Some patients forego colonoscopy not just out of fear or distaste, but due to its high cost. Here, too, the breakthrough is significant. While traditional colonoscopies cost about about $1,500 per test, Prof. Arber's procedure is expected to cost much less ― $50 to $100 per test.

Prevention Is Still the Best Medicine

Prof. Arber recommends a number of preventative steps against colon cancer, especially by those at risk. "There are some lifestyle choices people can make to prevent malignancies," he says. "Eating well, exercise, and avoiding smoking and drinking are very important."

Prof. Arber is also working on a drug that prevents the growth of polyps in the colon.


'/>"/>

Contact: George Hunka
ghunka@aftau.org
212-742-9070
American Friends of Tel Aviv University
Source:Eurekalert  

Related medicine news :

1. Simple new method detects contaminants in life-saving drug
2. Simple brain mechanisms explain arbitrary human visual decisions
3. Research indicates need for effective HPV vaccine for women and men and a simple HPV screening test
4. Family Halloween Safety Can Be Fiendishly Simple
5. Simpler Test May Be Best for Diagnosing Blood Clots in Leg
6. Major study of opiate use in childrens hospitals provides simple steps to alleviate harm
7. Simple, inexpensive and objective tools for the assessment of mucosal inflammation: fecal markers
8. Novartis Makes Accessing Prescription Assistance and Disease Management Programs Simpler and Easier for Patients
9. Simple Procedure Improves Male Fertility
10. Simple ultrasound exam may predict osteoporosis risk
11. Symptom Screening Plus a Simple Blood Test Equals a 20 Percent Jump in Early Detection of Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
A simple blood test for colon cancer
(Date:4/28/2017)... LINCOLN, R.I. (PRWEB) , ... April 28, 2017 , ... Getting enough sleep affects much ... Sleep Foundation (NSF), going just 19 hours without sleep can compromise motor reaction time, which ... Awareness Week, and Amica Insurance is sharing the following tips from the NSF to help ...
(Date:4/28/2017)... ... April 28, 2017 , ... Date aired: ... , “Computers are everywhere and they’re here to stay,” said Sharon Kleyne on ... and Your Health on Voice America sponsored by Nature’s Tears® EyeMist®. So she ...
(Date:4/28/2017)... ... April 28, 2017 , ... The Radiology Business Management Association (RBMA) ... 2017-2018. The annual board election process has been in place since the RBMA was ... C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, MHA, CMM, FRBMA, as president. Dr. Dickerson ...
(Date:4/28/2017)... ... April 28, 2017 , ... Children and adolescents who ... experiences than children in the general population. That’s because foster care is designed ... family challenges. While no fault of their own, youth who have experienced trauma ...
(Date:4/28/2017)... ... April 28, 2017 , ... From ... College of Urgent Care Medicine will host industry leaders for the annual spring ... help those in the industry adapt to the issues currently affecting urgent care ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... The Mobile X-Ray product segment is the most attractive market ... period Mobile X-Ray segment is the largest segment ... market, which is estimated to be valued at more than ... 7% over the forecast period. Mobile X-Ray segment is expected ... Mn in 2017 over 2016. The segment,s revenue in the ...
(Date:4/19/2017)... 2017 Global Prostate Cancer Therapeutics Market: ... prostate cancer therapeutics market analyzes the current and ... of prostate cancer, launch of promising emerging therapies, ... new drugs & therapeutic biological products, and high ... lesser side effects are some of the drivers ...
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, ... antibody-centric, clinical-stage biopharmaceutical company developing new treatments for ... the closing of its previously announced underwritten public ... at a public offering price of $2.00 per ... estimated offering expenses payable by Sorrento.  The net ...
Breaking Medicine Technology: